Please login to the form below

Not currently logged in
Email:
Password:

X4 appoints John Celebi as COO

He joins from Igenica Biotherapeutics

X4 Pharmaceuticals John CelebiCambridge, Massachusetts-based X4 Pharmaceuticals has appointed John Celebi as its new chief operating officer.

Celebi brings over 20 years of biotech industry experience to the role, and will take on responsibility for X4's business development, operations and corporate development.

Most recently, he served as chief business officer of Igenica Biotherapeutics, and has previously held senior positions at Agilent Technologies, ArQule, Biogen and Cyclis Pharmaceuticals.

Paula Regan, president and chief executive of X4, said: “John has a tremendous knowledge-base for evolving an emerging biotech company across the range of critical business capabilities.

“His experience will be essential to achieving X4's mission of developing novel CXCR4 therapies that have the potential to make a significant impact in the cancer treatment landscape, and we look forward to tapping into his business-building expertise as we continue to pursue the development of X4P-001 and our portfolio of CXCR4 inhibitors.”

22nd June 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics